42 results about "Thromboxanes" patented technology

The invention relates to a method for the diagnosis of a medical condition in a subject, comprising the steps of measuring the concentration of one or more analytes, relevant for the diagnosis of said medical condition, in a urine sample; measuring the electrical conductivity of said urine sample; obtaining a normalized value for the analyte concentration by dividing said analyte concentration by the electrical conductivity; and determining whether said subject is suffering from said medical condition by means of comparing the normalized value with a pre-determined reference value. The medical condition to be diagnosed can be, for example, an acute cardiac condition for which the relevant urinary analyte can be one or more thromboxanes.

The present invention relates to enantiomeric forms of hepoxilin analogs of Formula I-VIII, pharmaceutical compositions thereof, a method for the separation of said enantiomeric forms of hepoxilin analogs comprising applying said hepoxilin to a chiral phase HPLC column and eluting said hepoxilin with an alkane and alcohol solvent mixture. Said enantiomeric forms of hepoxilin analogs of Formula I-VIII were found to be useful in controlling the biological effects of PPAR mediated transcriptional control for the treatment of diseases such as cancer, thromboxane-mediated diseases and for modulating intracellular calcium concentration.

The invention describes novel substituted aryl compounds that are cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and / or, optionally, at least one therapeutic agent, such as, steroids, nonsterodal anti-inflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, H2 antagonists, antineoplastic agents, antiplatelet agents, thrombin inhibitors, thromboxane inhibitors, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton-pump-inhibitors, isoprostane inhibitors, and mixtures thereof. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, and, optionally, at least one nitric oxide donor, and / or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and / or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and / or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and / or preventing renal toxicity or other toxicities; for treating and / or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.

The invention relates to an early diagnosis marker for lung cancer and a diagnosis kit and application. Thromboxane can be used as the early diagnosis marker for the lung cancer, and comparison of thromboxane contents of experiment groups and control groups shows that the contents of the thromboxane in the experiment groups and the control groups are very remarkably different, the thromboxane is applicable to early identification and diagnosis of lung cancer and has good popularization and application values, and a novel clinical diagnosis method is provided for early diagnosis of lung cancer.

Kits are provided that can be used to determine a thromboxane B2 metabolite level and a creatinine level in a biological sample, particularly a human urine sample. This information can be used to optimize aspirin dosage in a patient. The present invention further includes calibrant preparations. In some embodiments, these calibrants comprise urine, particularly human urine that is identified in repeated trials to provide a consistent and reproduceable level of thromboxane B2 metabolite. As such, they function as control preparations that reduce error from intra-assay sampling measurements.

A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH2)x; Z is selected from the group consisting of and (CR2)x, x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, —COOR, —CH2OR1, —C(O)N(R1)2, —CH2N(R1)2—CH═N—OH and —CH2SR1 radicals wherein R is a C1 to C10 alkyl, phenyl or benzyl and R1 is R or hydrogen; or a pharmaceutically acceptable salt thereof.

The present invention concerns a compound consisting of RNA, in particular RNA extracted from yeast, a pharmaceutical composition comprising such RNA and a method for the treatment of inflammatory and inflammatory-related disorders comprising administering to a patient in need of such treatment a pharmaceutical composition comprising an amount effective to ameliorate the symptoms of inflammation or inflammatory-related disorder of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent. The exogenous yeast RNA used in the present invention has a pronounced membrane-stabilizing action in a wide range of concentrations. At the same time, yeast RNA normalizes metabolism of arachidonic acid and levels of its key metabolites, thromboxane and leukotriene. Its anti-inflammatory action is accompanied by normalization of the activity of NO-synthetase and anti-oxidant activity.

The present invention is directed to methods of treating and / or ameliorating muscular dystrophy and / or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist.

The present invention pertains to Cimiracemate A and related compounds that are useful as inhibitors of 5 -lipoxygenase (5-1. OX) activity and various proinflammatory mediators such as lipoxins, leukotrienes (e.g., LTA4, LTB4, LTC4, LTD4, and LTE4), prostaglandins, and thromboxanes. The present invention also provides therapeutic methods and compositions for treatment of inflammation and inflammatory conditions, including allergenic reactions, diseases associated with cell proliferation, neoangiogenesis, and cardiovascular diseases.

There is provided a pain relieving substance made of an eicosanoid-absorbent substance and a carrier. The eicosanoid-absorbent substance may be an eicosanoid enzyme, antibody and / or acid moiety binder. The eicosanoids may be prostaglantins, thromboxanes, leukotrienes, lipoxins and hydroxyl and hydroperoxy fatty acids and mixtures thereof. The eicosanoid-absorbent substance may be delivered in a liquid carrier such as a gel or lotion or may be delivered by a solid carrier such as a tampon, sponge, etc.

The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH / tonicity adjustment agent.